OS Therapies (OSTX) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for OS Therapies (OSTX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 7.35M (-16.48%) | 8.80M (+134.04%) | 3.76M (+50.40%) | 2.50M (+90.84%) | 1.31M (+50.57%) | 870K (-28.10%) | 1.21M (+202.50%) | 400K (+11.11%) | 360K (-64.71%) | 1.02M (+126.67%) | 450K (-54.55%) | 990K (+32.00%) | 750K |
Selling General And Administrative | 2.82M (-11.60%) | 3.19M (+2.24%) | 3.12M (+33.33%) | 2.34M (-36.59%) | 3.69M (+75.71%) | 2.10M (+70.73%) | 1.23M (+223.68%) | 380K (+40.74%) | 270K (+92.86%) | 140K (-17.65%) | 170K (-67.31%) | 520K (+79.31%) | 290K |
Operating Expenses | 10M (-15.18%) | 12M (+74.27%) | 6.88M (+42.15%) | 4.84M (-3.20%) | 5.00M (+68.35%) | 2.97M (+21.72%) | 2.44M (+212.82%) | 780K (+23.81%) | 630K (-45.69%) | 1.16M (+87.10%) | 620K (-59.21%) | 1.52M (+44.76%) | 1.05M |
Depreciation And Amortization | 120K (-66.67%) | 360K | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||
Operating Income | -10.17M (-15.18%) | -11.99M (+74.27%) | -6.88M (+42.15%) | -4.84M (-3.20%) | -5.00M (+68.35%) | -2.97M (+21.72%) | -2.44M (+212.82%) | -780.00K (+23.81%) | -630.00K (-45.69%) | -1.16M (+87.10%) | -620.00K (-59.21%) | -1.52M (+44.76%) | -1.05M |
Ebit | -10.17M (-15.18%) | -11.99M (+74.27%) | -6.88M (+42.15%) | -4.84M (-3.20%) | -5.00M (+68.35%) | -2.97M (+21.72%) | -2.44M (+212.82%) | -780.00K (+23.81%) | -630.00K (-45.69%) | -1.16M (+87.10%) | -620.00K (-59.21%) | -1.52M (+44.76%) | -1.05M |
EBITDA | -10.04M (-15.84%) | -11.93M (+73.40%) | -6.88M (+51.54%) | -4.54M (-9.20%) | -5.00M (+68.92%) | -2.96M (+21.31%) | -2.44M (+212.82%) | -780.00K (+23.81%) | -630.00K (-45.22%) | -1.15M (+85.48%) | -620.00K (-59.21%) | -1.52M (+44.76%) | -1.05M |
Other Income / Expenses | |||||||||||||
Interest Expense | 80K | - | - | - | - | 10K (-97.73%) | 440K (-43.59%) | 780K (-6.02%) | 830K (+167.74%) | 310K (-77.04%) | 1.35M (+36.36%) | 990K (+23.75%) | 800K |
Net Interest Income | - | - | - | - | - | 830K | - | - | -830.00K | 800K | - | - | -800.00K |
Other Non Operating Income | -230.00K (+360.00%) | -50.00K | - | 300K (-73.21%) | 1.12M | -2.07M (+370.45%) | -440.00K (-43.59%) | -780.00K (-6.02%) | -830.00K (-75.94%) | -3.45M (+155.56%) | -1.35M (+36.36%) | -990.00K (+23.75%) | -800.00K |
Net Income | |||||||||||||
Net Income From Continuing Operations | -10.40M (-22.73%) | -13.46M (+95.64%) | -6.88M (+51.54%) | -4.54M (+17.01%) | -3.88M (+29.77%) | -2.99M (+3.82%) | -2.88M (+84.62%) | -1.56M (+6.85%) | -1.46M (0.00%) | -1.46M (-25.89%) | -1.97M (-21.51%) | -2.51M (+35.68%) | -1.85M |
Net Income | -10.40M (-22.73%) | -13.46M (+95.64%) | -6.88M (+51.54%) | -4.54M (+17.01%) | -3.88M (+29.77%) | -2.99M (+3.82%) | -2.88M (+84.62%) | -1.56M (+6.85%) | -1.46M (0.00%) | -1.46M (-25.89%) | -1.97M (-21.51%) | -2.51M (+35.68%) | -1.85M |